24The filarial nematode Brugia malayi represents a leading cause of disability in the 25 developing world, causing lymphatic filariasis in nearly 40 million people. Currently 26 available drugs are not well-suited to mass drug administration efforts, so new 27 treatments are urgently required. One potential vulnerability is the endosymbiotic 28 bacteria Wolbachia-present in many filariae-which is vital to the worm. 29Genome scale metabolic networks have been used to study prokaryotes and protists 30 and have proven valuable in identifying therapeutic targets, but only recently have been 31 applied to eukaryotic organisms. Here, we present iDC625, the first compartmentalized 32 metabolic model of a parasitic worm. We used this model to show how metabolic 33 pathway usage allows the worm to adapt to different environments, and predict a set of 34 99 reactions essential to the survival of B. malayi. We validated three of those reactions 35 with drug tests and demonstrated novel antifilarial properties for all three compounds. 36 37 resistance in these species against diethylcarbamazine (Eberhard et al., 1991), 60ivermectin (Awadzi et al., 2004; Eng et al., 2006), and albendazole (Schwab et al., 61 2005) has been reported for many years. 62An alternative strategy for treatment has been the use of traditional antibiotics to target 63 the endosymbiotic bacteria that live within most filarial nematodes. These bacteria are 64 from the genus Wolbachia, specific to each helminth, and found to be essential for adult 65 worm fitness and reproduction (Taylor et al., 2013). Targeting these bacteria with the 66 antibiotic doxycycline was shown to reduce numbers of Wolbachia present in the 67 worms, sterilize adult females, and reduce symptoms of lymphatic filariasis (Debrah et 68 al., 2009; Rao et al., 2012; Ghedin et al., 2009; Taylor et al., 2010). While antibiotic 69 treatment remains a viable option for individual patients, long treatment times and 70 contraindications for children and pregnant women limit its suitability for mass-drug 71 administration efforts (Taylor et al., 2010). This strategy is ongoing, as recent evidence 72 suggests that the commonly used antibiotic rifampicin may also possess filaricidal 73 activity, but these data are preliminary and have not yet been tested in humans 74 (Aljayyoussi et al., 2017). A more recent study proposes faster-acting antibiotics that 75 belong to the tetracycline class of drugs (Taylor et al., 2019). 76Considering the limitations of current treatment regimes, there is an urgent need to 77 identify new drug targets against filarial nematodes that directly impact adult worm 78 survival and, if possible, are specific enough to avoid the potential complications that 79 arise in regions co-endemic for O. volvulus or L. loa. Genome scale metabolic 80 reconstruction and constraint-based modelling have emerged as effective strategies to 81 identify critical metabolic enzymes and pathways (Oberhardt et al., 2008; Chavali et al., 82 2008; Lee et al., 2009; Song et al., 2013),...